Clinical Trials Browser

Interventional × zimberelimab × 90 days × Clear all

NCT05891171 2026-06-05

ARC-25

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05419479 2026-06-04

Switch Maintenance in Pancreatic

Phase 1/2 Suspended

Gastrointestinal

Pancreatic Neoplasms

NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Phase 1 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms, Cholangiocarcinoma

NCT04104672 2026-06-02

ARC-8

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05329766 2026-06-02

EDGE-Gastric

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05568095 2026-06-02

STAR-221

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04736173 2026-06-01

ARC-10

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05536141 2026-06-01

ARC-20

Phase 1 Recruiting

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT05633667 2026-06-01

VELOCITY-Lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05676931 2026-06-01

EDGE-Lung

Phase 2 Active not recruiting

Advanced Non-Small Cell Lung Cancer

NCT06431633 2026-05-18

ARIAN

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT04791839 2026-05-06

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07134556 2026-05-01

ADJUNCT

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT06532565 2026-04-21

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT04656535 2026-04-17

AB154 Combined With AB122 for Recurrent Glioblastoma

Phase EARLY_PHASE1 Active not recruiting

Glioblastoma, Recurrence

NCT06082960 2026-04-16

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT05130177 2026-03-31

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Phase 2 Active not recruiting

Melanoma

NCT07397611 2026-03-20

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Phase 2 Active not recruiting

Urothelial Bladder Carcinoma